{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:33:52Z","timestamp":1786988032704,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"am","delay-in-days":332,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ejca.2020.01.019","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T01:19:36Z","timestamp":1582939176000},"page":"32-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey"],"prefix":"10.1016","volume":"129","author":[{"given":"Alice","family":"Boil\u00e8ve","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Lillo-Le Lou\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Gaboriau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9626-3571","authenticated-orcid":false,"given":"Laurent","family":"Chouchana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Hillaire-Buys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3379-4065","authenticated-orcid":false,"given":"Mathieu","family":"Jozwiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.01.019_bib1","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.3390\/cancers2031717","article-title":"5-FU metabolism in cancer and orally-administrable 5-FU drugs","volume":"2","author":"Miura","year":"2010","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2020.01.019_bib2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1179::AID-CNCR1>3.0.CO;2-G","article-title":"A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma","volume":"80","author":"Machover","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.01.019_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004003","article-title":"Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients","volume":"3","author":"Gross","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2020.01.019_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s13691-016-0243-0","article-title":"Rechallenge with 5-fluorouracil in a patient who developed encephalopathy caused by 5-fluorouracil for colon cancer","volume":"5","author":"Yamada","year":"2016","journal-title":"Int Cancer Conf J"},{"key":"10.1016\/j.ejca.2020.01.019_bib5","series-title":"Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy. Medicine (Baltimore)","volume":"vol. 96","author":"Mitani","year":"2017"},{"key":"10.1016\/j.ejca.2020.01.019_bib6","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/bjc.1997.79","article-title":"High-dose 5-fluorouracil infusional therapy is associated with hyperammonaemia, lactic acidosis and encephalopathy","volume":"75","author":"Yeh","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2020.01.019_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00001813-199903000-00004","article-title":"Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5-fluorouracil with the complication of dehydration and infection","volume":"10","author":"Liaw","year":"1999","journal-title":"Anti Canc Drugs"},{"key":"10.1016\/j.ejca.2020.01.019_bib8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jns.2018.07.015","article-title":"Drug-induced coma after chemotherapy in intensive care unit: How to make the right diagnosis?","volume":"392","author":"Boil\u00e8ve","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.ejca.2020.01.019_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/CAD.0000000000000730","article-title":"5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy","volume":"30","author":"Boil\u00e8ve","year":"2019","journal-title":"Anti Canc Drugs"},{"key":"10.1016\/j.ejca.2020.01.019_bib10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1365-2125.2012.04185.x","article-title":"Trends of reporting of \u2018serious\u2019vs. \u2018non-serious\u2019 adverse drug reactions over time: a study in the French PharmacoVigilance Database","volume":"74","author":"Moulis","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ejca.2020.01.019_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.ejca.2020.01.019_bib12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"D\u00e9pistage du d\u00e9ficit en dihydropyrimidine deshydrog\u00e9nase (DPD) et s\u00e9curisation des chimioth\u00e9rapies \u00e0 base de fluoropyrimidines\u202f: mise au point et recommandations nationales du GPCO-Unicancer et du RNPGx","volume":"105","author":"Loriot","year":"2018","journal-title":"Bulletin Du Cancer"},{"key":"10.1016\/j.ejca.2020.01.019_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1001\/archneur.1970.00480260061008","article-title":"Biochemical basis for fluorouracil neurotoxicity. The role of Krebs cycle inhibition by fluoroacetate","volume":"23","author":"Koenig","year":"1970","journal-title":"Arch Neurol"},{"key":"10.1016\/j.ejca.2020.01.019_bib14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ccc.2005.05.002","article-title":"Unmasked adult-onset urea cycle disorders in the critical care setting","volume":"21","author":"Summar","year":"2005","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.ejca.2020.01.019_bib15","series-title":"GeneReviews\u00ae","article-title":"Urea cycle disorders overview","author":"Ah Mew","year":"1993"},{"key":"10.1016\/j.ejca.2020.01.019_bib16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00134-017-4845-6","article-title":"Understanding hepatic encephalopathy","volume":"44","author":"Weiss","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ejca.2020.01.019_bib17","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00280-011-1666-0","article-title":"5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases","volume":"68","author":"Cordier","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ejca.2020.01.019_bib18","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-05-2665","article-title":"Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen","volume":"12","author":"Ichikawa","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2020.01.019_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.bulcan.2018.02.001","article-title":"[Dihydropyrimidine d\u00e9hydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: update and recommendations of the French GPCO-Unicancer and RNPGx networks]","volume":"105","author":"Loriot","year":"2018","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ejca.2020.01.019_bib20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2020.01.019_bib21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1159\/000320032","article-title":"Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity","volume":"56","author":"Kim","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ejca.2020.01.019_bib22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma","year":"2017","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:29Z","timestamp":1760732789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920300344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":22,"alternative-id":["S0959804920300344"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.01.019","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"5-Fluorouracil-induced hyperammonaemic encephalopathy: A French national survey","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}